VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascul...(ich monitored safety of the drug through...),Health
| HOME >> MEDICINE >> TECHNOLOGY |
ich monitored safety of the drug throughout both trials.
A third Phase 2 clinical trial is currently underway to measure reductions in plaque inflammation following dosing with VIA-2291 as measured with state- of-the-art FDG-PET imaging technology and assessment of standard biomarker measurements of inflammation in patients with ACS.
Conference Call Information
VIA will hold a conference call on Monday, November 10 at 8:30 a.m. ET (5:30 a.m. PT) to discuss this announcement. To participate in the conference call, please dial 888-684-1280 for domestic callers and 913-312-0952 for international callers. A telephone replay of the conference call will be available through Friday, November 14, 2008. To access the replay, please dial 888-203-1112 for domestic callers and 719-457-0820 for international callers and reference conference replay passcode 1268443.
A live audio webcast of the call can be accessed from the investor section of the VIA website, http://www.viapharmaceuticals.com beginning at 8:30am ET on Monday, November 10. The webcast will be archived for 30 days following the presentation.
About VIA-2291
VIA-2291 is designed to complement current standard of care therapies that treat cardiac risk factors, such as statins, antiplatelet and blood pressure medications. VIA-2291 is initially targeted to address the secondary prevention market for patients who have already suffered a major adverse cardiac event, but eventually could be beneficial to the broader 15.8 million patients in the U.S. who have coronary artery disease. VIA has exclusive worldwide rights to develop and commercialize VIA-2291. VIA-2291 has been tested in more that 1,300 patients in clinical trials.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the
development of compounds for the treatment of cardiovascular disease. VIA
is buildi
'/>"/>
| SOURCE VIA Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
10. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
11. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |